Synthesis of new ferulic/lipoic/comenic acid-melatonin hybrids as antioxidants and Nrf2 activators via Ugi reaction

References

• 1. Sies H. Oxidative stress: oxidants and antioxidants. Exp. Physiol. 82(2), 291–295 (1997).
  Medline CASGoogle Scholar
• 2. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol. Rev. 78(2), 547–581 (1998).
  Medline CASGoogle Scholar
• 3. Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int. J. Biomed. Sci. 4(2), 89–96 (2008).
  Medline CASGoogle Scholar
• 4. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MNVR. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J. Control. Rel. 113(3), 189–207 (2006).
  Medline CASGoogle Scholar
• 5. von Bernhardi R, Eugenín J. Alzheimer’s disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid. Redox Signal. 16(9), 974–1031 (2012).
  Medline CASGoogle Scholar
• 6. Fukuda M, Kanou F, Shimada N et al. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer’s disease. Biomed. Res. 30(4), 227–233 (2009).
  Medline CASGoogle Scholar
• 7. Moreira PI, Nunomura A, Nakamura M et al. Nucleic acid oxidation in Alzheimer disease. Free Radic. Biol. Med. 44(8), 1493–1505 (2008).
  Medline CASGoogle Scholar
• 8. Sultana R, Merocci P, Mangialasche F, Cecchetti R, Baglioni M, Butterfield DA. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer’s disease: insights into the role of oxidative stress in Alzheimer’s disease and initial investigations into a potential biomarker for this dementing disorder. J. Alzheimer Dis. 24(1), 77–84 (2011).
  Medline CASGoogle Scholar
• 9. Rosini M, Somini E, Milelli A, Melchiorre C. Oxidative stress in Alzheimer’s disease: are we connecting the dots? J. Med. Chem. 57(7), 2821–2831 (2014).
  Medline CASGoogle Scholar
• 10. Unzeta M, Esteban G, Bolea I et al. Multi-target directed donepezil-like ligands for Alzheimer’s disease. Front. Neurosci. doi.org/10.3389/fnins.2016.00205 (2016).
  Google Scholar
• 11. Vriend J, Reiter RJ. Melatonin feedback on clock genes: a theory involving the proteasome. J. Pineal Res. 58(1), 1–11 (2015).
  Medline CASGoogle Scholar
• 12. Rosales-Corral SA, Acuña-Castroviejo D, Coto-Montes A et al. Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin. J. Pineal Res. 52(2), 167–202 (2012).
  Medline CASGoogle Scholar
• 13. Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin’s role in antiaging mechanisms. J. Pineal Res. 55(4), 325–356 (2013).
  Medline CASGoogle Scholar
• 14. Poeggeler B, Reiter RJ, Hardeland R, Tan D-X, Barlow-Walden LR. Melatonin and structurally-related, endogenous indoles act as potent electron donors and radical scavengers in vitro. Redox Report 2(3), 179–184 (1996).
  Medline CASGoogle Scholar
• 15. Manchester LC, Coto-Montes A, Boga JA et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J. Pineal Res. 59(4), 403–419 (2015).
  Medline CASGoogle Scholar
• 16. Du Plessis SS, Hagenaar K, Lampiao F. The in vitro effects of melatonin on human sperm function and its scavenging activities on NO and ROS. Andrologia 42(2), 112–116 (2010).
  MedlineGoogle Scholar
• 17. Zavodnik IB, Domanski AV, Lapshina EA, Bryszewska M, Reiter RJ. Melatonin directly scavenges free radicals generated in red blood cells and a cell-free system: chemiluminescence measurements and theoretical calculations. Life Sci. 79(4), 391–400 (2006).
  Medline CASGoogle Scholar
• 18. Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem. Pharmacol. 80(12), 1844–1852 (2010).
  Medline CASGoogle Scholar
• 19. Tan D-X, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr. J. 1(4), 57–60 (1993).
  Google Scholar
• 20. Zhang H-M, Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J. Pineal Res. 57(2), 131–146 (2014).
  Medline CASGoogle Scholar
• 21. Graf E. Antioxidant potential of ferulic acid. Free Radic. Biol. Med. 13(4), 435–448 (1992).
  Medline CASGoogle Scholar
• 22. Kim K-H, Lee B, Kim Y-R et al. Evaluating protective and therapeutic effects of α-lipoic acid on cisplatin-induced ototoxicity. Cell Death Dis. 9(8), 827 (2018).
  MedlineGoogle Scholar
• 23. Shurygina LV, Zlishcheva EI, Kravtsova AN, Kravtsov AA. Antioxidant and antiamnestic effects of potassium comenate and comenic acid under conditions of normobaric hypoxia with hypercapnia. Bull. Exp. Biol. Med. 163(3), 344–348 (2017).
  Medline CASGoogle Scholar
• 24. Vriend J, Reiter RJ. The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol. Cell. Endocrinol. 401, 213–220 (2015).
  Medline CASGoogle Scholar
• 25. Benchekroun M, Romero A, Egea J et al. The antioxidant additive approach for Alzheimer’s disease therapy: new ferulic (lipoic) acid plus melatonin modified tacrines as cholinesterases inhibitors, direct antioxidants, and nuclear factor (erythroid-derived 2)-like 2 activators. J. Med. Chem. 59(21), 9967–9973 (2016).
  Medline CASGoogle Scholar
• 26. Pachón-Angona I, Refouvelet B, Andrýs R et al. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy. J. Enzyme Inhib. Med. Chem. 34(1), 479–489 (2019).
  Medline CASGoogle Scholar
• 27. Dávalos A, Gómez-Cordovés C, Bartolomé B. Extending applicability of the oxygen radical absorbance capacity (ORAC–fluorescein) assay. J. Agric. Food Chem. 52(1), 48–54 (2004).
  Medline CASGoogle Scholar
• 28. Dgachi Y, Bautista-Aguilera OM, Benchekroun M et al. Synthesis and biological evaluation of benzochromenopyrimidinones as cholinesterase inhibitors and potent antioxidant, non-hepatotoxic agents for Alzheimer’s disease. Molecules 21(5), 634 (2016).
  Google Scholar
• 29. Benchekroun M, Pachón-Angona I, Luzet V et al. Synthesis, antioxidant and Aβ anti-aggregation properties of new ferulic, caffeic and lipoic acid derivatives obtained by the Ugi four-component reaction. Bioorg. Chem. 85, 221–228 (2019).
  Medline CASGoogle Scholar
• 30. Dávalos A, Gómez-Cordovés C, Bartolomé B. Extending applicability of the oxygen radical absorbance capacity (ORAC–fluorescein) assay. J. Agric. Food Chem. 52(1), 48–54 (2004).
  Medline CASGoogle Scholar
• 31. Parada E, Buendia I, León R et al. Neuroprotective effect of melatonin against ischemia is partially mediated by α-7 nicotinic receptor modulation and HO-1 overexpression. J. Pineal Res. 56(2), 204–212 (2014).
  Medline CASGoogle Scholar
• 32. Wang XJ, Hayes JD, Wolf CR. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of Nrf2 by cancer chemotherapeutic agents. Cancer Res. 66(22), 10983–10994 (2006).
  Medline CASGoogle Scholar
• 33. Zhang J, Zhou X, Wu W, Wang J, Xie H, Wu Z. Regeneration of glutathione by α-lipoic acid via Nrf2/ARE signaling pathway alleviates cadmium-induced HepG2 cell toxicity. Environ. Toxicol. Pharmacol. 51, 30–37 (2017).
  Medline CASGoogle Scholar
• 34. Pilar Valdecantos M, Prieto-Hontoria PL, Pardo V et al. Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes. Free Radic. Biol. Med. 84, 263–278 (2015).
  MedlineGoogle Scholar
• 35. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J. The transcription factor Nrf2 as a new therapeutic target in Parkinson’s disease. Expert Opin. Ther. Targets 13(3), 319–329 (2009).
  Medline CASGoogle Scholar
• 36. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci. 28(50), 13574–13581 (2008).
  Medline CASGoogle Scholar